文献速递心脏核医学

基于深度学习的99mTc-焦磷酸盐SPECT/CT定量用于心脏淀粉样变性

Deep Learning-Enabled Quantification of 99mTc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis.
PubMed 文献 · J Nucl Med · 2024-07-01

本研究纳入299例疑似转甲状腺素蛋白心脏淀粉样变性(ATTR CA)患者,利用深度学习从CT衰减图分割心脏结构并应用于衰减校正SPECT图像,实现99mTc-焦磷酸盐的自动容积定量。心脏焦磷酸盐活性(CPA)和累及体积(VOI)对ATTR CA诊断的AUC分别为0.989和0.988,CPA的AUC显著高于心/对侧比值(P=0.046)。各定量指标均与心血管死亡或心衰住院复合终点风险升高相关(每SD增加的HR为1.41至1.84)。

要点

  • 深度学习分割CT衰减图可实现99mTc-焦磷酸盐SPECT的自动容积定量。
  • CPA和VOI对ATTR CA的诊断AUC分别为0.989和0.988。
  • CPA的AUC显著高于心/对侧比值(P=0.046)。

核心结论

  • 基于配准CT衰减图的深度学习分割不受放射性示踪剂摄取模式影响,可对99mTc-焦磷酸盐等热区SPECT成像实现全自动定量。
  • 该方法可准确识别ATTR CA患者,并可能在风险预测中发挥作用。

研究设计与样本

  • 纳入因疑似ATTR CA接受99mTc-焦磷酸盐SPECT/CT显像的患者,共299例,中位年龄76岁。
  • ATTR CA依据标准标准判定,共诊断83例(27.8%)。
  • 使用基础深度学习模型从CT衰减图分割心脏腔室和心肌,再应用于衰减校正SPECT图像以定量放射性示踪剂活性。
  • 采用受试者工作特征曲线下面积(AUC)评估靶/本底比值(TBR)、心脏焦磷酸盐活性(CPA)和累及体积(VOI)的诊断准确性,并评估其与心血管死亡或心衰住院复合终点的关联。

主要发现

  • CPA对ATTR CA的AUC为0.989(95%CI 0.974-1.00),VOI的AUC为0.988(95%CI 0.973-1.00),两者预测性能最高。
  • TBR的AUC为0.979(95%CI 0.964-0.995)。
  • CPA的AUC显著高于心/对侧比值(AUC 0.975,95%CI 0.952-0.998;P=0.046)。
  • 23例ATTR CA患者发生心血管死亡或心衰住院。
  • 调整年龄后,建立TBR、CPA和VOI的所有方法均与事件风险升高相关,每SD增加的HR范围为1.41至1.84。

关键数值与推荐

  • CPA诊断ATTR CA的AUC为0.989(95%CI 0.974-1.00)。
  • VOI诊断ATTR CA的AUC为0.988(95%CI 0.973-1.00)。
  • TBR诊断ATTR CA的AUC为0.979(95%CI 0.964-0.995)。
  • 心/对侧比值诊断ATTR CA的AUC为0.975(95%CI 0.952-0.998)。
  • 调整年龄后,TBR、CPA和VOI每SD增加与复合终点风险的HR范围为1.41至1.84。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transthyretin cardiac amyloidosis (ATTR CA) is increasingly recognized as a cause of heart failure in older patients, with 99mTc-pyrophosphate imaging frequently used to establish the diagnosis. Visual interpretation of SPECT images is the gold standard for interpretation but is inherently subjective. Manual quantitation of SPECT myocardial 99mTc-pyrophosphate activity is time-consuming and not performed clinically. We evaluated a deep learning approach for fully automated volumetric quantitation of 99mTc-pyrophosphate using segmentation of coregistered anatomic structures from CT attenuation maps. Methods: Patients who underwent SPECT/CT 99mTc-pyrophosphate imaging for suspected ATTR CA were included. Diagnosis of ATTR CA was determined using standard criteria. Cardiac chambers and myocardium were segmented from CT attenuation maps using a foundational deep learning model and then applied to attenuation-corrected SPECT images to quantify radiotracer activity. We evaluated the diagnostic accuracy of target-to-background ratio (TBR), cardiac pyrophosphate activity (CPA), and volume of involvement (VOI) using the area under the receiver operating characteristic curve (AUC). We then evaluated associations with the composite outcome of cardiovascular death or heart failure hospitalization. Results: In total, 299 patients were included (median age, 76 y), with ATTR CA diagnosed in 83 (27.8%) patients. CPA (AUC, 0.989; 95% CI, 0.974-1.00) and VOI (AUC, 0.988; 95% CI, 0.973-1.00) had the highest prediction performance for ATTR CA. The next highest AUC was for TBR (AUC, 0.979; 95% CI, 0.964-0.995). The AUC for CPA was significantly higher than that for heart-to-contralateral ratio (AUC, 0.975; 95% CI, 0.952-0.998; P = 0.046). Twenty-three patients with ATTR CA experienced cardiovascular death or heart failure hospitalization. All methods for establishing TBR, CPA, and VOI were associated with an increased risk of events after adjustment for age, with hazard ratios ranging from 1.41 to 1.84 per SD increase. Conclusion: Deep learning segmentation of coregistered CT attenuation maps is not affected by the pattern of radiotracer uptake and allows for fully automatic quantification of hot-spot SPECT imaging such as 99mTc-pyrophosphate. This approach can be used to accurately identify patients with ATTR CA and may play a role in risk prediction.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Miller RJH, Shanbhag A, Michalowska AM, et al. Deep Learning-Enabled Quantification of 99mTc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis. J Nucl Med. 2024. PMID: 38724278. doi:10.2967/jnumed.124.267542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。